Stifel Financial Corp Bei Gene, Ltd. Transaction History

Stifel Financial Corp

$93.2 Billion
Q3 2024

A detailed history of Stifel Financial Corp transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Stifel Financial Corp holds 12,807 shares of BGNE stock, worth $2.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,807

Previous 17,173 25.42%

Holding current value

$2.29 Million

Previous $2.45 Million 17.35%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$143.93 - $224.51 $628,398 - $980,210	-4,366 Reduced 25.42%	12,807 $2.88 Million
Q2 2024 Aug 13, 2024	SELL	$129.52 - $174.32 $42,223 - $56,828	-326 Reduced 1.86%	17,173 $2.45 Million
Q1 2024 May 13, 2024	BUY	$141.8 - $181.47 $714,955 - $914,971	5,042 Added 40.48%	17,499 $2.74 Million
Q4 2023 Feb 12, 2024	SELL	$158.67 - $201.58 $56,486 - $71,762	-356 Reduced 2.78%	12,457 $2.25 Million
Q3 2023 Nov 13, 2023	SELL	$179.87 - $225.13 $241,745 - $302,574	-1,344 Reduced 9.49%	12,813 $2.3 Million
Q2 2023 Aug 14, 2023	SELL	$178.3 - $266.78 $255,682 - $382,562	-1,434 Reduced 9.2%	14,157 $2.52 Million
Q1 2023 May 12, 2023	BUY	$215.53 - $274.5 $27,587 - $35,136	128 Added 0.83%	15,591 $3.36 Million
Q4 2022 Feb 13, 2023	SELL	$125.51 - $229.3 $32,883 - $60,076	-262 Reduced 1.67%	15,463 $3.4 Million
Q3 2022 Nov 14, 2022	SELL	$131.8 - $202.24 $9,094 - $13,954	-69 Reduced 0.44%	15,725 $2.12 Million
Q2 2022 Aug 15, 2022	BUY	$121.11 - $216.05 $61,281 - $109,321	506 Added 3.31%	15,794 $2.56 Million
Q1 2022 May 13, 2022	BUY	$146.52 - $269.56 $177,728 - $326,976	1,213 Added 8.62%	15,288 $2.88 Million
Q4 2021 Feb 14, 2022	BUY	$248.56 - $389.34 $47,474 - $74,363	191 Added 1.38%	14,075 $3.81 Million
Q3 2021 Nov 15, 2021	BUY	$249.6 - $403.14 $134,784 - $217,695	540 Added 4.05%	13,884 $5.04 Million
Q2 2021 Aug 13, 2021	BUY	$292.75 - $367.01 $42,448 - $53,216	145 Added 1.1%	13,344 $4.58 Million
Q1 2021 May 14, 2021	BUY	$260.64 - $382.12 $756,637 - $1.11 Million	2,903 Added 28.2%	13,199 $4.59 Million
Q4 2020 Feb 12, 2021	SELL	$221.31 - $316.61 $190,990 - $273,234	-863 Reduced 7.73%	10,296 $2.66 Million
Q3 2020 Nov 16, 2020	BUY	$189.18 - $286.44 $396,332 - $600,091	2,095 Added 23.11%	11,159 $3.2 Million
Q2 2020 Aug 14, 2020	SELL	$123.9 - $195.41 $87,101 - $137,373	-703 Reduced 7.2%	9,064 $1.71 Million
Q1 2020 May 14, 2020	BUY	$121.84 - $173.19 $21,200 - $30,135	174 Added 1.81%	9,767 $1.19 Million
Q4 2019 Feb 13, 2020	SELL	$115.78 - $208.34 $14,935 - $26,875	-129 Reduced 1.33%	9,593 $1.59 Million
Q3 2019 Nov 13, 2019	BUY	$120.61 - $148.29 $550,825 - $677,240	4,567 Added 88.59%	9,722 $1.18 Million
Q2 2019 Aug 14, 2019	BUY	$113.99 - $146.86 $2,393 - $3,084	21 Added 0.41%	5,155 $624,000
Q1 2019 May 14, 2019	BUY	$122.82 - $151.83 $159,788 - $197,530	1,301 Added 33.94%	5,134 $701,000
Q4 2018 Feb 13, 2019	BUY	$107.01 - $175.15 $30,176 - $49,392	282 Added 7.94%	3,833 $538,000
Q3 2018 Nov 13, 2018	BUY	$152.62 - $189.66 $541,953 - $673,482	3,551 New	3,551 $613,000

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.

Account

Stifel Financial Corp Bei Gene, Ltd. Transaction History